nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP3A4—bone cancer	0.719	1	CbGaD
Nefazodone—Domperidone—CYP3A4—bone cancer	0.000657	0.238	CrCbGaD
Nefazodone—Aripiprazole—CYP3A4—bone cancer	0.000508	0.184	CrCbGaD
Nefazodone—Trazodone—CYP3A4—bone cancer	0.000505	0.183	CrCbGaD
Nefazodone—Prochlorperazine—CYP3A4—bone cancer	0.000452	0.164	CrCbGaD
Nefazodone—Decreased appetite—Cisplatin—bone cancer	0.000419	0.00174	CcSEcCtD
Nefazodone—Bronchitis—Epirubicin—bone cancer	0.000418	0.00173	CcSEcCtD
Nefazodone—Pneumonia—Methotrexate—bone cancer	0.000417	0.00173	CcSEcCtD
Nefazodone—Gastritis—Doxorubicin—bone cancer	0.000412	0.00171	CcSEcCtD
Nefazodone—Pain—Cisplatin—bone cancer	0.000412	0.00171	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000411	0.0017	CcSEcCtD
Nefazodone—Alanine aminotransferase increased—Doxorubicin—bone cancer	0.000411	0.0017	CcSEcCtD
Nefazodone—Dysuria—Epirubicin—bone cancer	0.000407	0.00169	CcSEcCtD
Nefazodone—Abdominal distension—Doxorubicin—bone cancer	0.000405	0.00168	CcSEcCtD
Nefazodone—Stomatitis—Methotrexate—bone cancer	0.000404	0.00167	CcSEcCtD
Nefazodone—Conjunctivitis—Methotrexate—bone cancer	0.000403	0.00167	CcSEcCtD
Nefazodone—Asthma—Doxorubicin—bone cancer	0.000402	0.00167	CcSEcCtD
Nefazodone—Dysphagia—Doxorubicin—bone cancer	0.000402	0.00167	CcSEcCtD
Nefazodone—Influenza—Doxorubicin—bone cancer	0.000402	0.00167	CcSEcCtD
Nefazodone—Pollakiuria—Epirubicin—bone cancer	0.000402	0.00167	CcSEcCtD
Nefazodone—Sweating—Methotrexate—bone cancer	0.000397	0.00165	CcSEcCtD
Nefazodone—Photosensitivity reaction—Epirubicin—bone cancer	0.000397	0.00165	CcSEcCtD
Nefazodone—Feeling abnormal—Cisplatin—bone cancer	0.000397	0.00165	CcSEcCtD
Nefazodone—Weight increased—Epirubicin—bone cancer	0.000396	0.00164	CcSEcCtD
Nefazodone—Haematuria—Methotrexate—bone cancer	0.000395	0.00164	CcSEcCtD
Nefazodone—Weight decreased—Epirubicin—bone cancer	0.000393	0.00163	CcSEcCtD
Nefazodone—Angina pectoris—Doxorubicin—bone cancer	0.000392	0.00163	CcSEcCtD
Nefazodone—Epistaxis—Methotrexate—bone cancer	0.000391	0.00162	CcSEcCtD
Nefazodone—Pneumonia—Epirubicin—bone cancer	0.00039	0.00162	CcSEcCtD
Nefazodone—Bronchitis—Doxorubicin—bone cancer	0.000387	0.0016	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000384	0.00159	CcSEcCtD
Nefazodone—Body temperature increased—Cisplatin—bone cancer	0.000381	0.00158	CcSEcCtD
Nefazodone—Stomatitis—Epirubicin—bone cancer	0.000378	0.00157	CcSEcCtD
Nefazodone—Conjunctivitis—Epirubicin—bone cancer	0.000377	0.00156	CcSEcCtD
Nefazodone—Urinary tract infection—Epirubicin—bone cancer	0.000377	0.00156	CcSEcCtD
Nefazodone—Dysuria—Doxorubicin—bone cancer	0.000376	0.00156	CcSEcCtD
Nefazodone—Haemoglobin—Methotrexate—bone cancer	0.000374	0.00155	CcSEcCtD
Nefazodone—Haemorrhage—Methotrexate—bone cancer	0.000372	0.00154	CcSEcCtD
Nefazodone—Hepatitis—Methotrexate—bone cancer	0.000372	0.00154	CcSEcCtD
Nefazodone—Sweating—Epirubicin—bone cancer	0.000372	0.00154	CcSEcCtD
Nefazodone—Pollakiuria—Doxorubicin—bone cancer	0.000372	0.00154	CcSEcCtD
Nefazodone—Haematuria—Epirubicin—bone cancer	0.00037	0.00153	CcSEcCtD
Nefazodone—Pharyngitis—Methotrexate—bone cancer	0.000369	0.00153	CcSEcCtD
Nefazodone—Photosensitivity reaction—Doxorubicin—bone cancer	0.000367	0.00152	CcSEcCtD
Nefazodone—Weight increased—Doxorubicin—bone cancer	0.000366	0.00152	CcSEcCtD
Nefazodone—Epistaxis—Epirubicin—bone cancer	0.000366	0.00152	CcSEcCtD
Nefazodone—Weight decreased—Doxorubicin—bone cancer	0.000364	0.00151	CcSEcCtD
Nefazodone—Sinusitis—Epirubicin—bone cancer	0.000364	0.00151	CcSEcCtD
Nefazodone—Pneumonia—Doxorubicin—bone cancer	0.000361	0.0015	CcSEcCtD
Nefazodone—Visual impairment—Methotrexate—bone cancer	0.000358	0.00149	CcSEcCtD
Nefazodone—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000356	0.00147	CcSEcCtD
Nefazodone—Hypersensitivity—Cisplatin—bone cancer	0.000355	0.00147	CcSEcCtD
Nefazodone—Bradycardia—Epirubicin—bone cancer	0.000354	0.00147	CcSEcCtD
Nefazodone—Erythema multiforme—Methotrexate—bone cancer	0.000352	0.00146	CcSEcCtD
Nefazodone—Haemoglobin—Epirubicin—bone cancer	0.00035	0.00145	CcSEcCtD
Nefazodone—Stomatitis—Doxorubicin—bone cancer	0.00035	0.00145	CcSEcCtD
Nefazodone—Rhinitis—Epirubicin—bone cancer	0.000349	0.00145	CcSEcCtD
Nefazodone—Conjunctivitis—Doxorubicin—bone cancer	0.000349	0.00145	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—bone cancer	0.000349	0.00145	CcSEcCtD
Nefazodone—Hepatitis—Epirubicin—bone cancer	0.000348	0.00144	CcSEcCtD
Nefazodone—Haemorrhage—Epirubicin—bone cancer	0.000348	0.00144	CcSEcCtD
Nefazodone—Tinnitus—Methotrexate—bone cancer	0.000347	0.00144	CcSEcCtD
Nefazodone—Hypoaesthesia—Epirubicin—bone cancer	0.000346	0.00144	CcSEcCtD
Nefazodone—Asthenia—Cisplatin—bone cancer	0.000345	0.00143	CcSEcCtD
Nefazodone—Pharyngitis—Epirubicin—bone cancer	0.000345	0.00143	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—bone cancer	0.000344	0.00143	CcSEcCtD
Nefazodone—Oedema peripheral—Epirubicin—bone cancer	0.000343	0.00142	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—bone cancer	0.000342	0.00142	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—bone cancer	0.000338	0.0014	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—bone cancer	0.000337	0.0014	CcSEcCtD
Nefazodone—Visual impairment—Epirubicin—bone cancer	0.000335	0.00139	CcSEcCtD
Nefazodone—Chills—Methotrexate—bone cancer	0.000334	0.00138	CcSEcCtD
Nefazodone—Diarrhoea—Cisplatin—bone cancer	0.000329	0.00137	CcSEcCtD
Nefazodone—Erythema multiforme—Epirubicin—bone cancer	0.000329	0.00136	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—bone cancer	0.000329	0.00136	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—bone cancer	0.000328	0.00136	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—bone cancer	0.000324	0.00135	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—bone cancer	0.000324	0.00134	CcSEcCtD
Nefazodone—Perphenazine—CYP3A4—bone cancer	0.000323	0.117	CrCbGaD
Nefazodone—Flushing—Epirubicin—bone cancer	0.000323	0.00134	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—bone cancer	0.000323	0.00134	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—bone cancer	0.000322	0.00134	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—bone cancer	0.000322	0.00134	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—bone cancer	0.00032	0.00133	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—bone cancer	0.00032	0.00133	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—bone cancer	0.000317	0.00132	CcSEcCtD
Nefazodone—Quetiapine—CYP3A4—bone cancer	0.000317	0.115	CrCbGaD
Nefazodone—Dysgeusia—Methotrexate—bone cancer	0.000317	0.00131	CcSEcCtD
Nefazodone—Back pain—Methotrexate—bone cancer	0.000313	0.0013	CcSEcCtD
Nefazodone—Chills—Epirubicin—bone cancer	0.000312	0.00129	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—bone cancer	0.00031	0.00129	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—bone cancer	0.000308	0.00128	CcSEcCtD
Nefazodone—Vomiting—Cisplatin—bone cancer	0.000306	0.00127	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—bone cancer	0.000305	0.00127	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—bone cancer	0.000304	0.00126	CcSEcCtD
Nefazodone—Rash—Cisplatin—bone cancer	0.000304	0.00126	CcSEcCtD
Nefazodone—Dermatitis—Cisplatin—bone cancer	0.000303	0.00126	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—bone cancer	0.0003	0.00125	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—bone cancer	0.0003	0.00125	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—bone cancer	0.000299	0.00124	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—bone cancer	0.000299	0.00124	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—bone cancer	0.000299	0.00124	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—bone cancer	0.000297	0.00123	CcSEcCtD
Nefazodone—Back pain—Epirubicin—bone cancer	0.000293	0.00122	CcSEcCtD
Nefazodone—Malaise—Methotrexate—bone cancer	0.000292	0.00121	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—bone cancer	0.000291	0.00121	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—bone cancer	0.000291	0.00121	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—bone cancer	0.00029	0.0012	CcSEcCtD
Nefazodone—Chills—Doxorubicin—bone cancer	0.000289	0.0012	CcSEcCtD
Nefazodone—Nausea—Cisplatin—bone cancer	0.000286	0.00119	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—bone cancer	0.000286	0.00118	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—bone cancer	0.000285	0.00118	CcSEcCtD
Nefazodone—Cough—Methotrexate—bone cancer	0.000282	0.00117	CcSEcCtD
Nefazodone—Ill-defined disorder—Epirubicin—bone cancer	0.000281	0.00117	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—bone cancer	0.00028	0.00116	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—bone cancer	0.00028	0.00116	CcSEcCtD
Nefazodone—Agitation—Epirubicin—bone cancer	0.000278	0.00115	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—bone cancer	0.000276	0.00115	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—bone cancer	0.000276	0.00114	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—bone cancer	0.000276	0.00114	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—bone cancer	0.000276	0.00114	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—bone cancer	0.000274	0.00114	CcSEcCtD
Nefazodone—Malaise—Epirubicin—bone cancer	0.000273	0.00113	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—bone cancer	0.000272	0.00113	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—bone cancer	0.000272	0.00113	CcSEcCtD
Nefazodone—Syncope—Epirubicin—bone cancer	0.000272	0.00113	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—bone cancer	0.000271	0.00112	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—bone cancer	0.000271	0.00112	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—bone cancer	0.000269	0.00112	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—bone cancer	0.000268	0.00111	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—bone cancer	0.000266	0.0011	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—bone cancer	0.000266	0.0011	CcSEcCtD
Nefazodone—Cough—Epirubicin—bone cancer	0.000264	0.0011	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—bone cancer	0.000264	0.0011	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—bone cancer	0.000264	0.0011	CcSEcCtD
Nefazodone—Convulsion—Epirubicin—bone cancer	0.000262	0.00109	CcSEcCtD
Nefazodone—Infection—Methotrexate—bone cancer	0.000262	0.00109	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—bone cancer	0.000262	0.00108	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—bone cancer	0.00026	0.00108	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—bone cancer	0.000259	0.00107	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—bone cancer	0.000259	0.00107	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—bone cancer	0.000258	0.00107	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—bone cancer	0.000258	0.00107	CcSEcCtD
Nefazodone—Arthralgia—Epirubicin—bone cancer	0.000258	0.00107	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—bone cancer	0.000258	0.00107	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—bone cancer	0.000257	0.00107	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—bone cancer	0.000255	0.00106	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—bone cancer	0.000255	0.00106	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—bone cancer	0.000253	0.00105	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—bone cancer	0.000252	0.00105	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—bone cancer	0.000252	0.00104	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—bone cancer	0.000252	0.00104	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—bone cancer	0.000251	0.00104	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—bone cancer	0.000251	0.00104	CcSEcCtD
Nefazodone—Confusional state—Epirubicin—bone cancer	0.000249	0.00103	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—bone cancer	0.000248	0.00103	CcSEcCtD
Nefazodone—Oedema—Epirubicin—bone cancer	0.000247	0.00103	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—bone cancer	0.000247	0.00103	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—bone cancer	0.000247	0.00102	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—bone cancer	0.000246	0.00102	CcSEcCtD
Nefazodone—Infection—Epirubicin—bone cancer	0.000246	0.00102	CcSEcCtD
Nefazodone—Cough—Doxorubicin—bone cancer	0.000245	0.00101	CcSEcCtD
Nefazodone—Shock—Epirubicin—bone cancer	0.000243	0.00101	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—bone cancer	0.000243	0.00101	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—bone cancer	0.000242	0.001	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—bone cancer	0.000242	0.001	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—bone cancer	0.000241	0.001	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—bone cancer	0.000241	0.000998	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—bone cancer	0.000239	0.000991	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—bone cancer	0.000239	0.000991	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—bone cancer	0.000239	0.00099	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—bone cancer	0.000239	0.00099	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—bone cancer	0.000239	0.00099	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—bone cancer	0.000238	0.000986	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—bone cancer	0.000237	0.000984	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—bone cancer	0.000236	0.000978	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—bone cancer	0.000236	0.000977	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—bone cancer	0.000236	0.000977	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—bone cancer	0.000235	0.000974	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—bone cancer	0.000233	0.000968	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—bone cancer	0.000233	0.000964	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—bone cancer	0.000231	0.000958	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—bone cancer	0.000231	0.000957	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—bone cancer	0.00023	0.000952	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—bone cancer	0.000229	0.000949	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—bone cancer	0.000229	0.000949	CcSEcCtD
Nefazodone—Infection—Doxorubicin—bone cancer	0.000227	0.000943	CcSEcCtD
Nefazodone—Pain—Methotrexate—bone cancer	0.000226	0.000937	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—bone cancer	0.000225	0.000934	CcSEcCtD
Nefazodone—Shock—Doxorubicin—bone cancer	0.000225	0.000933	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—bone cancer	0.000224	0.000929	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—bone cancer	0.000224	0.000927	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—bone cancer	0.000223	0.000926	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—bone cancer	0.000222	0.000921	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—bone cancer	0.000221	0.000917	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—bone cancer	0.00022	0.000914	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—bone cancer	0.00022	0.000912	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—bone cancer	0.000218	0.000904	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—bone cancer	0.000218	0.000903	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—bone cancer	0.000218	0.000903	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—bone cancer	0.000216	0.000896	CcSEcCtD
Nefazodone—Decreased appetite—Epirubicin—bone cancer	0.000215	0.000891	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—bone cancer	0.000214	0.000887	CcSEcCtD
Nefazodone—Pain—Epirubicin—bone cancer	0.000211	0.000877	CcSEcCtD
Nefazodone—Constipation—Epirubicin—bone cancer	0.000211	0.000877	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—bone cancer	0.00021	0.00087	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—bone cancer	0.000209	0.000866	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—bone cancer	0.000209	0.000866	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000208	0.000864	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—bone cancer	0.000207	0.000858	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—bone cancer	0.000205	0.000852	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—bone cancer	0.000204	0.000846	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—bone cancer	0.000204	0.000845	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—bone cancer	0.000203	0.000843	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—bone cancer	0.000202	0.000838	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—bone cancer	0.000201	0.000835	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—bone cancer	0.000199	0.000825	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—bone cancer	0.000196	0.000815	CcSEcCtD
Nefazodone—Pain—Doxorubicin—bone cancer	0.000196	0.000811	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—bone cancer	0.000196	0.000811	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—bone cancer	0.000195	0.000811	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—bone cancer	0.000195	0.000811	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—bone cancer	0.000195	0.000807	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—bone cancer	0.00019	0.000786	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—bone cancer	0.000189	0.000782	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—bone cancer	0.000187	0.000776	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—bone cancer	0.000187	0.000775	CcSEcCtD
Nefazodone—Hypersensitivity—Epirubicin—bone cancer	0.000182	0.000755	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—bone cancer	0.000182	0.000754	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—bone cancer	0.000181	0.00075	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—bone cancer	0.000181	0.00075	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—bone cancer	0.000181	0.00075	CcSEcCtD
Nefazodone—Asthenia—Epirubicin—bone cancer	0.000177	0.000736	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—bone cancer	0.000175	0.000725	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—bone cancer	0.000175	0.000725	CcSEcCtD
Nefazodone—Diarrhoea—Epirubicin—bone cancer	0.000169	0.000702	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—bone cancer	0.000169	0.000699	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—bone cancer	0.000168	0.000697	CcSEcCtD
Nefazodone—Rash—Methotrexate—bone cancer	0.000167	0.000691	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—bone cancer	0.000166	0.00069	CcSEcCtD
Nefazodone—Headache—Methotrexate—bone cancer	0.000166	0.000686	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—bone cancer	0.000164	0.000681	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—bone cancer	0.000163	0.000678	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—bone cancer	0.000162	0.000671	CcSEcCtD
Nefazodone—Vomiting—Epirubicin—bone cancer	0.000157	0.000652	CcSEcCtD
Nefazodone—Nausea—Methotrexate—bone cancer	0.000157	0.000651	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—bone cancer	0.000157	0.000649	CcSEcCtD
Nefazodone—Rash—Epirubicin—bone cancer	0.000156	0.000647	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—bone cancer	0.000156	0.000646	CcSEcCtD
Nefazodone—Headache—Epirubicin—bone cancer	0.000155	0.000642	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—bone cancer	0.000151	0.000627	CcSEcCtD
Nefazodone—Nausea—Epirubicin—bone cancer	0.000147	0.000609	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—bone cancer	0.000145	0.000603	CcSEcCtD
Nefazodone—Rash—Doxorubicin—bone cancer	0.000144	0.000598	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—bone cancer	0.000144	0.000598	CcSEcCtD
Nefazodone—Headache—Doxorubicin—bone cancer	0.000143	0.000594	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—bone cancer	0.000136	0.000564	CcSEcCtD
Nefazodone—ADRA1B—AMPK Signaling—TP53—bone cancer	6.67e-05	0.00178	CbGpPWpGaD
Nefazodone—CYP2D6—Biological oxidations—CYP3A4—bone cancer	6.55e-05	0.00175	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—JUN—bone cancer	6.47e-05	0.00173	CbGpPWpGaD
Nefazodone—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	6.46e-05	0.00173	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—RGS1—bone cancer	6.41e-05	0.00171	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—GRM4—bone cancer	6.41e-05	0.00171	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	6.39e-05	0.00171	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—NT5C3A—bone cancer	6.33e-05	0.00169	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	6.31e-05	0.00168	CbGpPWpGaD
Nefazodone—HTR2A—GPCR ligand binding—SMO—bone cancer	6.29e-05	0.00168	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR ligand binding—SMO—bone cancer	6.15e-05	0.00164	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—RGS1—bone cancer	6.11e-05	0.00163	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—GRM4—bone cancer	6.11e-05	0.00163	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—GRM4—bone cancer	6.08e-05	0.00162	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—RGS1—bone cancer	6.08e-05	0.00162	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NDUFA12—bone cancer	6.03e-05	0.00161	CbGpPWpGaD
Nefazodone—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	5.98e-05	0.0016	CbGpPWpGaD
Nefazodone—ADRA1A—AMPK Signaling—TP53—bone cancer	5.92e-05	0.00158	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—GRM1—bone cancer	5.84e-05	0.00156	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—RGS1—bone cancer	5.82e-05	0.00155	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—GRM4—bone cancer	5.82e-05	0.00155	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—GRM4—bone cancer	5.81e-05	0.00155	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—RGS1—bone cancer	5.81e-05	0.00155	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—GRM1—bone cancer	5.81e-05	0.00155	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR ligand binding—SMO—bone cancer	5.72e-05	0.00153	CbGpPWpGaD
Nefazodone—SLC6A3—Transmission across Chemical Synapses—MDM2—bone cancer	5.7e-05	0.00152	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—GRM4—bone cancer	5.69e-05	0.00152	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—RGS1—bone cancer	5.69e-05	0.00152	CbGpPWpGaD
Nefazodone—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	5.65e-05	0.00151	CbGpPWpGaD
Nefazodone—CYP2D6—Biological oxidations—GSTP1—bone cancer	5.6e-05	0.0015	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—GRM1—bone cancer	5.56e-05	0.00148	CbGpPWpGaD
Nefazodone—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	5.53e-05	0.00148	CbGpPWpGaD
Nefazodone—HTR1A—SIDS Susceptibility Pathways—JUN—bone cancer	5.52e-05	0.00148	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NDUFA12—bone cancer	5.52e-05	0.00147	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	5.34e-05	0.00143	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.33e-05	0.00142	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—GRM1—bone cancer	5.3e-05	0.00142	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—RGS1—bone cancer	5.29e-05	0.00141	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—GRM4—bone cancer	5.29e-05	0.00141	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—RGS1—bone cancer	5.28e-05	0.00141	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—GRM4—bone cancer	5.28e-05	0.00141	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—GRM1—bone cancer	5.27e-05	0.00141	CbGpPWpGaD
Nefazodone—SLC6A3—Neuronal System—BRAF—bone cancer	5.21e-05	0.00139	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—GRM4—bone cancer	5.17e-05	0.00138	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—RGS1—bone cancer	5.17e-05	0.00138	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—SPARC—bone cancer	5.11e-05	0.00137	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—GRM1—bone cancer	5.05e-05	0.00135	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—GRM1—bone cancer	5.04e-05	0.00135	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—NT5C3A—bone cancer	4.99e-05	0.00133	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—GRM1—bone cancer	4.94e-05	0.00132	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—GRM4—bone cancer	4.8e-05	0.00128	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—RGS1—bone cancer	4.8e-05	0.00128	CbGpPWpGaD
Nefazodone—HTR2A—SIDS Susceptibility Pathways—JUN—bone cancer	4.77e-05	0.00127	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—GNA11—bone cancer	4.68e-05	0.00125	CbGpPWpGaD
Nefazodone—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.6e-05	0.00123	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—GRM1—bone cancer	4.59e-05	0.00123	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—GRM1—bone cancer	4.58e-05	0.00122	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NT5C3A—bone cancer	4.58e-05	0.00122	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—GRM1—bone cancer	4.48e-05	0.0012	CbGpPWpGaD
Nefazodone—SLC6A3—Neuronal System—MDM2—bone cancer	4.36e-05	0.00117	CbGpPWpGaD
Nefazodone—SLC6A4—Circadian rythm related genes—TP53—bone cancer	4.27e-05	0.00114	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—IL3—bone cancer	4.24e-05	0.00113	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NDUFA12—bone cancer	4.17e-05	0.00111	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—GRM1—bone cancer	4.17e-05	0.00111	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	3.96e-05	0.00106	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NDUFA12—bone cancer	3.93e-05	0.00105	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—GNA11—bone cancer	3.76e-05	0.001	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—GNA11—bone cancer	3.74e-05	0.000999	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—SMO—bone cancer	3.73e-05	0.000997	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—SMO—bone cancer	3.71e-05	0.000992	CbGpPWpGaD
Nefazodone—CYP3A4—Biological oxidations—GSTP1—bone cancer	3.66e-05	0.000978	CbGpPWpGaD
Nefazodone—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	3.61e-05	0.000965	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—GRM4—bone cancer	3.61e-05	0.000964	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—RGS1—bone cancer	3.61e-05	0.000964	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—RGS1—bone cancer	3.59e-05	0.000959	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—GRM4—bone cancer	3.59e-05	0.000959	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—GNA11—bone cancer	3.58e-05	0.000957	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—SMO—bone cancer	3.56e-05	0.00095	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NT5C3A—bone cancer	3.45e-05	0.000922	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—GRM4—bone cancer	3.44e-05	0.000918	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—RGS1—bone cancer	3.44e-05	0.000918	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—GNA11—bone cancer	3.41e-05	0.000912	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—IL3—bone cancer	3.41e-05	0.000911	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—GNA11—bone cancer	3.4e-05	0.000907	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—IL3—bone cancer	3.39e-05	0.000906	CbGpPWpGaD
Nefazodone—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.34e-05	0.000893	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NT5C3A—bone cancer	3.25e-05	0.000869	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—GNA11—bone cancer	3.25e-05	0.000869	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—GNA11—bone cancer	3.25e-05	0.000868	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—IL3—bone cancer	3.25e-05	0.000867	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—SMO—bone cancer	3.23e-05	0.000862	CbGpPWpGaD
Nefazodone—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	3.2e-05	0.000855	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—GNA11—bone cancer	3.18e-05	0.00085	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—SMO—bone cancer	3.16e-05	0.000844	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—GRM1—bone cancer	3.13e-05	0.000836	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GRM4—bone cancer	3.12e-05	0.000833	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RGS1—bone cancer	3.12e-05	0.000833	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—GRM1—bone cancer	3.11e-05	0.000832	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL3—bone cancer	3.1e-05	0.000827	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL3—bone cancer	3.08e-05	0.000823	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RGS1—bone cancer	3.05e-05	0.000816	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GRM4—bone cancer	3.05e-05	0.000816	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—GRM1—bone cancer	2.98e-05	0.000796	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—GNA11—bone cancer	2.96e-05	0.000789	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—GNA11—bone cancer	2.95e-05	0.000788	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL3—bone cancer	2.95e-05	0.000788	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—IL3—bone cancer	2.95e-05	0.000787	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	2.94e-05	0.000785	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—SMO—bone cancer	2.93e-05	0.000784	CbGpPWpGaD
Nefazodone—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.9e-05	0.000775	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—GNA11—bone cancer	2.89e-05	0.000772	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—IL3—bone cancer	2.88e-05	0.00077	CbGpPWpGaD
Nefazodone—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—bone cancer	2.84e-05	0.000759	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RGS1—bone cancer	2.84e-05	0.000758	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GRM4—bone cancer	2.84e-05	0.000758	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	2.83e-05	0.000757	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—PLAU—bone cancer	2.78e-05	0.000743	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—ENO2—bone cancer	2.77e-05	0.000741	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GRM1—bone cancer	2.7e-05	0.000722	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—GNA11—bone cancer	2.68e-05	0.000717	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—IL3—bone cancer	2.68e-05	0.000716	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL3—bone cancer	2.67e-05	0.000714	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GRM1—bone cancer	2.65e-05	0.000707	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL3—bone cancer	2.62e-05	0.0007	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—DHFR—bone cancer	2.57e-05	0.000687	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NDUFA12—bone cancer	2.57e-05	0.000686	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	2.55e-05	0.000682	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GRM1—bone cancer	2.46e-05	0.000657	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL3—bone cancer	2.43e-05	0.00065	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GNA11—bone cancer	2.4e-05	0.000642	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SMO—bone cancer	2.21e-05	0.000589	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SMO—bone cancer	2.19e-05	0.000586	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—ENO2—bone cancer	2.19e-05	0.000584	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—CYP3A4—bone cancer	2.18e-05	0.000582	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NT5C3A—bone cancer	2.13e-05	0.000568	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SMO—bone cancer	2.1e-05	0.000561	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—DHFR—bone cancer	2.03e-05	0.000542	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—GNA11—bone cancer	2.02e-05	0.000539	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.01e-05	0.000536	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—GNA11—bone cancer	2.01e-05	0.000536	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—ENO2—bone cancer	2e-05	0.000535	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—GNA11—bone cancer	1.92e-05	0.000513	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SMO—bone cancer	1.91e-05	0.000509	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GNA11—bone cancer	1.9e-05	0.000506	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—ATF1—bone cancer	1.88e-05	0.000501	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SMO—bone cancer	1.87e-05	0.000498	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—ATF1—bone cancer	1.87e-05	0.000498	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—GSTP1—bone cancer	1.86e-05	0.000498	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—DHFR—bone cancer	1.86e-05	0.000497	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL3—bone cancer	1.83e-05	0.000489	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL3—bone cancer	1.82e-05	0.000486	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—ATF1—bone cancer	1.79e-05	0.000477	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—GNA11—bone cancer	1.74e-05	0.000466	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL3—bone cancer	1.74e-05	0.000465	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GNA11—bone cancer	1.74e-05	0.000464	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SMO—bone cancer	1.73e-05	0.000463	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—CYP3A4—bone cancer	1.72e-05	0.000459	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—GNA11—bone cancer	1.71e-05	0.000456	CbGpPWpGaD
Nefazodone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.69e-05	0.00045	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ATF1—bone cancer	1.62e-05	0.000433	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ATF1—bone cancer	1.59e-05	0.000424	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—GNA11—bone cancer	1.59e-05	0.000424	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL3—bone cancer	1.58e-05	0.000422	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—CYP3A4—bone cancer	1.58e-05	0.000421	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFBR2—bone cancer	1.56e-05	0.000418	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFBR2—bone cancer	1.56e-05	0.000416	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL3—bone cancer	1.55e-05	0.000413	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ENO2—bone cancer	1.51e-05	0.000404	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFBR2—bone cancer	1.49e-05	0.000398	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ATF1—bone cancer	1.47e-05	0.000394	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IGF1R—bone cancer	1.47e-05	0.000393	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—GSTP1—bone cancer	1.47e-05	0.000393	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IGF1R—bone cancer	1.46e-05	0.000391	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL3—bone cancer	1.44e-05	0.000384	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ENO2—bone cancer	1.43e-05	0.000381	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—DHFR—bone cancer	1.4e-05	0.000375	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IGF1R—bone cancer	1.4e-05	0.000374	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFBR2—bone cancer	1.35e-05	0.000361	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—GSTP1—bone cancer	1.35e-05	0.00036	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFBR2—bone cancer	1.32e-05	0.000353	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—DHFR—bone cancer	1.32e-05	0.000353	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GNA11—bone cancer	1.31e-05	0.00035	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IGF1R—bone cancer	1.27e-05	0.00034	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IGF1R—bone cancer	1.24e-05	0.000333	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GNA11—bone cancer	1.24e-05	0.00033	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFBR2—bone cancer	1.23e-05	0.000328	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CYP3A4—bone cancer	1.19e-05	0.000318	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1R—bone cancer	1.16e-05	0.000309	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CYP3A4—bone cancer	1.12e-05	0.000299	CbGpPWpGaD
Nefazodone—ADRA2A—Hemostasis—TP53—bone cancer	1.12e-05	0.000299	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KIT—bone cancer	1.07e-05	0.000285	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KIT—bone cancer	1.06e-05	0.000284	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—GSTP1—bone cancer	1.02e-05	0.000272	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KIT—bone cancer	1.02e-05	0.000272	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—BRAF—bone cancer	1e-05	0.000268	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—BRAF—bone cancer	9.98e-06	0.000267	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—EGFR—bone cancer	9.72e-06	0.00026	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—EGFR—bone cancer	9.67e-06	0.000258	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PTGS2—bone cancer	9.66e-06	0.000258	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—GSTP1—bone cancer	9.58e-06	0.000256	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—BRAF—bone cancer	9.55e-06	0.000255	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ENO2—bone cancer	9.32e-06	0.000249	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—EGFR—bone cancer	9.26e-06	0.000247	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KIT—bone cancer	9.22e-06	0.000246	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KIT—bone cancer	9.03e-06	0.000241	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—BRAF—bone cancer	8.67e-06	0.000232	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—DHFR—bone cancer	8.64e-06	0.000231	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—BRAF—bone cancer	8.49e-06	0.000227	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MDM2—bone cancer	8.41e-06	0.000225	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—EGFR—bone cancer	8.4e-06	0.000224	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KIT—bone cancer	8.39e-06	0.000224	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MDM2—bone cancer	8.36e-06	0.000223	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—EGFR—bone cancer	8.23e-06	0.00022	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GNA11—bone cancer	8.08e-06	0.000216	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MDM2—bone cancer	8.01e-06	0.000214	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—BRAF—bone cancer	7.89e-06	0.000211	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—bone cancer	7.64e-06	0.000204	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—bone cancer	7.62e-06	0.000203	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—JUN—bone cancer	7.31e-06	0.000195	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—JUN—bone cancer	7.27e-06	0.000194	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MDM2—bone cancer	7.26e-06	0.000194	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MDM2—bone cancer	7.11e-06	0.00019	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—bone cancer	7.11e-06	0.00019	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—bone cancer	7.07e-06	0.000189	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—bone cancer	6.98e-06	0.000186	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—JUN—bone cancer	6.96e-06	0.000186	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—bone cancer	6.77e-06	0.000181	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MDM2—bone cancer	6.61e-06	0.000176	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—JUN—bone cancer	6.31e-06	0.000169	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—bone cancer	6.26e-06	0.000167	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—JUN—bone cancer	6.18e-06	0.000165	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—bone cancer	6.14e-06	0.000164	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—bone cancer	6.01e-06	0.000161	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—bone cancer	5.74e-06	0.000153	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—JUN—bone cancer	5.74e-06	0.000153	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—bone cancer	5.71e-06	0.000153	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—bone cancer	5.59e-06	0.000149	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—bone cancer	5.47e-06	0.000146	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—bone cancer	5.27e-06	0.000141	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—bone cancer	4.96e-06	0.000133	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—bone cancer	4.96e-06	0.000133	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—bone cancer	4.86e-06	0.00013	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—bone cancer	4.82e-06	0.000129	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—bone cancer	4.8e-06	0.000128	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—bone cancer	4.59e-06	0.000123	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—bone cancer	4.51e-06	0.000121	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—bone cancer	4.17e-06	0.000111	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—bone cancer	4.08e-06	0.000109	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—bone cancer	3.79e-06	0.000101	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—bone cancer	3.25e-06	8.67e-05	CbGpPWpGaD
